Alzheimer contract research offering
Assessing in-vivo efficacy of experimental Alzheimer treatments in extensively validated, proprietary transgenic mouse models.
The core expertise of reMYND’s CRO is the assessment of the pharmacokinetics and –dynamics of experimental Alzheimer drugs in our proprietary Alzheimer mouse models expressing the clinical APP-London allele, either as single transgene or in combination with clinical alleles of human PS1 or TAU.
Fill in the form and download:
- A concise overview of our contract research offering
- A description of our transgenic models
- A glance at our portfolio of behavior, biochemistry and immunohistochemistry read-outs
NEW: A4-assay for oligomeric Abeta
For all inquiries please contact Dr. An Tanghe at cro@remynd.com.
Share
Related to
More information
Fill in the form and download a concise overview of our contract research offering.
